

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C07K 16/8		A1	(11) International Publication Number: WO 00/12758 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19655 (22) International Filing Date: 1 September 1999 (01.09.99)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/098,880 2 September 1998 (02.09.98) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment 218, 350 Elan Village Lane, San Jose, CA 95134 (US).			
(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).			
(54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS			
(57) Abstract			
<p>The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	CN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING VARIOUS CANCERS**

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating various cancers,
particularly gynecologic cancer including ovarian, uterine
endometrial and breast cancer, and lung cancer.

BACKGROUND OF THE INVENTION

10 The American Cancer Society has estimated that over
560,000 Americans will die this year from cancer. Cancer is
the second leading cause of death in the United States,
exceeded only by heart disease. It has been estimated that
over one million new cancer cases will be diagnosed in 1999
15 alone.

In women, gynecologic cancers account for more than one-fourth of the malignancies.

Of the gynecologic cancers, breast cancer is the most common. According to the Women's Cancer Network, 1 out of
20 every 8 women in the United States is at risk of developing breast cancer, and 1 out of every 28 women are at risk of dying from breast cancer. Approximately 77% of women diagnosed with breast cancer are over the age of 50. However, breast cancer is the leading cause of death in women
25 between the ages of 40 and 55.

Carcinoma of the ovary is another very common gynecologic cancer. Approximately one in 70 women will develop ovarian cancer during her lifetime. An estimated 14,500 deaths in 1995 resulted from ovarian cancer. It causes
30 more deaths than any other cancer of the female reproductive system. Ovarian cancer often does not cause any noticeable

- 2 -

symptoms. Some possible warning signals, however, are an enlarged abdomen due to an accumulation of fluid or vague digestive disturbances (discomfort, gas or distention) in women over 40; rarely there will be abnormal vaginal bleeding.

5 Periodic, complete pelvic examinations are important; a Pap test does not detect ovarian cancer. Annual pelvic exams are recommended for women over 40.

Also common in women is endometrial cancer or carcinoma of the lining of the uterus. According to the Women's Cancer 10 Center endometrial cancer accounts for approximately 13% of all malignancies in women. There are about 34,000 cases of endometrial cancer diagnosed in the United States each year.

Uterine sarcoma is another type of uterine malignancy much more rare as compared to other gynecologic cancers. In 15 uterine sarcoma, malignant cells start growing in the muscles or other supporting tissues of the uterus. Sarcoma of the uterus is different from cancer of the endometrium, a disease in which cancer cells start growing in the lining of the uterus. This uterine cancer usually begins after menopause. 20 Women who have received therapy with high-dose X-rays (external beam radiation therapy) to their pelvis are at a higher risk to develop sarcoma of the uterus. These X-rays are sometimes given to women to stop bleeding from the uterus.

Lung cancer is the second most prevalent type of cancer 25 for both men and women in the United States and is the most common cause of cancer death in both sexes. Lung cancer can result from a primary tumor originating in the lung or a secondary tumor which has spread from another organ such as the bowel or breast. Primary lung cancer is divided into 30 three main types; small cell lung cancer; non-small cell lung cancer; and mesothelioma. Small cell lung cancer is also called "Oat Cell" lung cancer because the cancer cells are a distinctive oat shape. There are three types of non-small cell lung cancer. These are grouped together because they behave 35 in a similar way and respond to treatment differently to small

- 3 -

cell lung cancer. The three types are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Squamous cell cancer is the most common type of lung cancer. It develops from the cells that line the airways. Adenocarcinoma 5 also develops from the cells that line the airways. However, adenocarcinoma develops from a particular type of cell that produces mucus (phlegm). Large cell lung cancer has been thus named because the cells look large and rounded when they are viewed under a microscope. Mesothelioma is a rare type of 10 cancer which affects the covering of the lung called the pleura. Mesothelioma is often caused by exposure to asbestos.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating each of these types of cancer are of critical importance to the outcome of the patient. In all 15 cases, patients diagnosed early in development of the cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with a cancer which has metastasized. New diagnostic methods which are more sensitive and specific for early detection of various 20 types of cancer are clearly needed.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating, *in vivo* imaging and treating selected cancers including, but not limited to, gynecologic cancers such as ovarian, breast 25 endometrial and/or uterine cancer, and lung cancer via detection of a Cancer Specific Genes (CSGs). Nine CGSs have been identified and refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. 30 In the alternative, what is meant by the nine CSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4,

- 4 -

5, 6, 7, 8 or 9. Fragments of the CSGs such as those depicted in SEQ ID NO:10, 11, 12, 13 or 14 can also be detected.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the selected cancer. For the purposes of this invention, by "selected cancer" it is meant to include gynecologic cancers such as ovarian, breast, endometrial and uterine cancer, and lung cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having a selected cancer which is not known to have metastasized by identifying a human patient suspected of having a selected cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CSG levels in the patient

- 5 -

versus the normal human control is associated with a cancer which has metastasized.

Also provided by the invention is a method of staging selected cancers in a human patient by identifying a human 5 patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing CSG levels in such cells, tissues, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in 10 CSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring selected 15 cancers in patients for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CSG; comparing the CSG levels in such cells, tissues, or 20 bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

25 Further provided is a method of monitoring the change in stage of selected cancers in humans having such cancer by looking at levels of CSG. The method comprises identifying a human patient having a selected cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from 30 such patient for CSG; comparing the CSG levels in such cells, tissue, or bodily fluid with levels of CSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the patient versus the normal human control is associated with a 35 cancer which is progressing and a decrease in the levels of

- 6 -

CSG is associated with a cancer which is regressing or in remission.

Further provided are antibodies against CSG or fragments of such antibodies which can be used to detect or image 5 localization of CSG in a patient for the purpose of detecting or diagnosing selected cancers. Such antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant to include 10 aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. 15 These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a CSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug 20 or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the 25 specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and 30 from reading the other parts of the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating selected

- 7 -

cancers by comparing levels of CSG with those of CSG in a normal human control. What is meant by levels of CSG as used herein is levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 5 1, 2, 3, 4, 5, 6, 7, 8 or 9. In the alternative, what is meant by levels of CSG as used herein is levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9 or levels of the gene comprising any of the polynucleotide sequences of 10 SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8 or 9. Fragments of CSGs such as those depicted in SEQ ID NO: 10, 11, 12, 13 and 14 can also be detected. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for 15 instance, a diagnostic assay in accordance with the invention for diagnosing over-expression of CSG protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of selected cancers. What is meant by "selected cancers" as used herein is a gynecologic 20 cancer such as ovarian, breast, endometrial or uterine cancer, or lung cancer.

Any of the 9 CSGs can be measured alone in the methods of the invention, or all together or any combination thereof. However, for methods relating to gynecologic cancers including 25 ovarian, breast, endometrial and uterine cancer, it is preferred that levels of CSG comprising SEQ ID NO: 1 or a fragment thereof be determined. Exemplary fragments of this CSG which can be detected are depicted in SEQ ID NO: 10, 11, 12, and 13. For methods relating to lung cancer and 30 gynecologic cancers including ovarian, endometrial and uterine, it is preferred that levels of CSG comprising SEQ ID NO: 2 or 9 be determined. Fragments of this CSG such as that depicted in SEQ ID NO: 14 can also be detected. For methods relating to ovarian cancer, determination of levels of CSG 35 comprising SEQ ID NO: 3 is also preferred.

- 8 -

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as CSG. Other cancer markers, in addition to CSG, useful in the present invention will depend on the cancer being tested 5 and are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of selected cancers by analyzing for changes in levels of CSG in cells, tissues or bodily fluids compared with 10 levels of CSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein a change in levels of CSG in the patient versus the normal human control is associated with the presence of a selected cancer.

Without limiting the instant invention, typically, for 15 a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, 20 tissues or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastases of selected cancers in a patient having a selected cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a 25 human cancer patient suspected of having a selected cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For example, in the case of ovarian cancer, patients 30 are typically diagnosed with ovarian cancer following surgical staging and monitoring of CA125 levels. Traditional detection methods are also available and well known for other selected cancers which can be diagnosed by determination of CSG levels in a patient.

- 9 -

In the present invention, determining the presence of CSG levels in cells, tissues or bodily fluid, is particularly useful for discriminating between a selected cancer which has not metastasized and a selected cancer which has metastasized.

5 Existing techniques have difficulty discriminating between cancers which have metastasized and cancers which have not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues or bodily fluid is CSG, and are compared with levels of CSG in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CSG in serum, this level is preferably compared with the level of CSG in serum 15 of a normal human patient. An increase in the CSG in the patient versus the normal human control is associated with a cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating 20 the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily 25 fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may also include samples from 30 a human patient that is determined by reliable methods to have a selected cancer which has not metastasized.

Staging

The invention also provides a method of staging selected cancers in human patients. The method comprises identifying 35 a human patient having a selected cancer and analyzing a

- 10 -

sample of cells, tissues or bodily fluid from such human patient for CSG. Then, the method compares CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a 5 normal human control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CSG is associated with a cancer which is regressing or in remission.

10 **Monitoring**

Further provided is a method of monitoring selected cancers in humans for the onset of metastasis. The method comprises identifying a human patient having a selected cancer that is not known to have metastasized; periodically analyzing 15 a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CSG levels in the human 20 patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of selected cancers in humans having such cancers. The method comprises identifying a human 25 patient having a selected cancer; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CSG; comparing the CSG levels in such cells, tissues or bodily fluid with levels of CSG in preferably the same cells, tissues or bodily fluid type of a normal human 30 control sample, wherein an increase in CSG levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CSG is associated with a cancer which is regressing in stage or in remission.

- 11 -

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

5 **Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as CSG of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include
10 radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein
15 in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds
20 specifically to CSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to CSG is
25 incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CSG binds
30 to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CSG.
35 Unattached reporter antibody is then washed out. Reagents for

- 12 -

peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to CSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to 5 the amount of CSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to CSG attached to a solid support and labeled CSG 10 and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of CSG in the sample.

Nucleic acid methods may be used to detect CSG mRNA as a marker for selected cancers. Polymerase chain reaction 15 (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of the various selected malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful 20 technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified 25 as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

30 Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the CSG gene is fixed to a substrate. The substrate may be of any suitable 35 type including but not limited to glass, nitrocellulose, nylon

- 13 -

or plastic. At least a portion of the DNA encoding the CSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

5 Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be
10 done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

15 Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.
20 First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on
25 the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or
30 subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue
35 extracts (homogenates or solubilized tissue) such as from

- 14 -

tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.

5 **In Vivo Antibody Use**

Antibodies against CSG can also be used *in vivo* in patients suspected of suffering from a selected cancer including lung cancer or gynecologic cancers such as ovarian, breast, endometrial or uterine cancer. Specifically, 10 antibodies against a CSG can be injected into a patient suspected of having a selected cancer for diagnostic and/or therapeutic purposes. The use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use 15 in the radioimmunoscinographic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of having recurrent colorectal cancer (Griffin et al. J. Clin. 20 Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against CSGs can be used in a similar manner. Labeled antibodies against a CSG can be 25 injected into patients suspected of having a selected cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or 30 Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). 35 Localization of the label permits determination of the spread

- 15 -

of the cancer. The amount of label within an organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with a selected cancer, injection 5 of an antibody against a CSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been 10 described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have 15 been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares *Cancer Supplement* 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine- 131 and Rhenium-186 can also be used for labeling of 20 antibodies against CSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded 25 oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

The present invention is further described by the following examples. These examples are provided solely to 30 illustrate the invention by reference to specific embodiments. The exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

- 16 -

EXAMPLES**Example 1:**

Identification of CSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte 5 Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps: selection of highly expressed organ specific genes based on the abundance 10 level of the corresponding EST in the targeted organ versus all the other organs; analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease. Selection of the candidates demonstrating component 15 ESTs were exclusively or more frequently found in tumor libraries. The CLASP allows the identification of highly expressed organ and cancer specific genes. A final manual in depth evaluation is then performed to finalize the CSGs selection.

20 **Table 1: CSG Sequences**

	SEQ ID NO:	Clone ID	Gene ID
	1	16656542	234617
	2	1283171	332459
	3	1649377	481154
25	4	236044H1	none assigned
	5	none assigned	255687
	6	none assigned	251313
	7	none assigned	12029
	8	none assigned	251804

30

The following examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail.

- 17 -

Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses 10 an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection 15 System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 20 or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained 25 using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene for every example in normal and cancer tissue were evaluated. Total RNA was extracted from normal tissues, cancer tissues, 30 and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to each target gene. The results are analyzed using the ABI PRISM 7700

- 18 -

Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

Measurement of Ovr110; Clone ID16656542; Gene ID 234617 (SEQ

5 ID NO:1, 10, 11, 12 or 13)

The absolute numbers depicted in Table 2 are relative levels of expression of Ovr110 (SEQ ID NO:1 or a fragment thereof as depicted in SEQ ID NO:10, 11, 12, or 13) in 12 normal different tissues. All the values are compared to 10 normal stomach (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Table 2: Relative Levels of Ovr110 Expression in Pooled Samples

	Tissue	NORMAL
15	colon	0.00
	endometrium	8.82
	kidney	7.19
	liver	0.36
20	ovary	1.19
	pancreas	21.41
	prostate	2.79
	small intestine	0.03
	spleen	0.00
25	00000000000000stoma	1.00
	testis	8.72
	uterus	0.93

The relative levels of expression in Table 2 show that Ovr110 is expressed at comparable levels in most of the normal 30 tissues analyzed. Pancreas, with a relative expression level of 21.41, endometrium (8.82), testis (8.72), and kidney (7.19) are the only tissues expressing high levels of Ovr110 mRNA.

The absolute numbers in Table 2 were obtained analyzing pools of samples of a particular tissue from different 35 individuals. They can not be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in Table 3.

- 19 -

The absolute numbers depicted in Table 3 are relative levels of expression of Ovr110 in 73 pairs of matching samples. All the values are compared to normal stomach (calibrator). A matching pair is formed by mRNA from the 5 cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 15 unmatched cancer samples (from ovary and mammary gland) and 14 unmatched normal samples (from ovary and mammary gland) were also tested.

10 **Table 3: Relative Levels of Ovr110 Expression in Individual Samples**

	Sample ID	Tissue	Cancer	Matching Normal Adjacent	Normal
	Ovr103X	Ovary 1	86.22	0.53	
	Ovr1040O	Ovary 2	168.31		
15	Ovr1157	Ovary 3	528.22		
	Ovr63A	Ovary 4	1.71		
	Ovr773O	Ovary 5	464.65		
	Ovr1005O	Ovary 6	18.32		
	Ovr1028	Ovary 7	7.78		
20	Ovr1118	Ovary 8	0.00		
	Ovr130X	Ovary 9	149.09		
	Ovr638A	Ovary 10	3.14		
	OvrA1B	Ovary 11	21.26		
	OvrA1C	Ovary 12	1.83		
25	OvrC36O	Ovary 13	0.52		
	Ovr18GA	Ovary 14			1.07
	Ovr20GA	Ovary 15			1.88
	Ovr25GA	Ovary 16			2.52
	Ovr206I	Ovary 17			2.51
30	Ovr32RA	Ovary 18			3.01

- 20 -

	Ovr35GA	Ovary 19			5.17
	Ovr40G	Ovary 20			0.45
	Ovr50GB	Ovary 21			2.69
	OvrC087	Ovary 22			0.47
5	OvrC179	Ovary 23			1.46
	OvrC004	Ovary 24			4.99
	OvrC007	Ovary 25			13.36
	OvrC109	Ovary 26			6.61
	MamS516	Mammary Gland 1	16.39	13.74	
	MamS621	Mammary Gland 2	826.70	4.60	
	MamS854	Mammary Gland 3	34.60	18.30	
10	Mam59X	Mammary Gland 4	721.57	27.00	
	MamS079	Mammary Gland 5	80.73	5.10	
	MamS967	Mammary Gland 6	6746.90	72.80	
	MamS127	Mammary Gland 7	7.00	20.00	
	MamB011X	Mammary Gland 8	1042.00	29.00	
15	Mam12B	Mammary Gland 9	1342.00		
	Mam82XI	Mammary Gland 10	507.00		
	MamS123	Mammary Gland 11	24.85	4.24	
	MamS699	Mammary Gland 12	84.74	5.54	
20	MamS997	Mammary Gland 13	482.71	11.84	
	Mam162X	Mammary Gland 14	15.73	10.59	

- 21 -

	MamA06X	Mammary Gland 15	1418.35	8.20	
	Mam603X	Mammary Gland 16	294.00		
	Mam699F	Mammary Gland 17	567.40	86.60	
	Mam12X	Mammary Gland 18	425.00	31.00	
5	MamA04	Mammary Gland 19			2.00
	Mam42DN	Mammary Gland 20	46.05	31.02	
	Utr23XU	Uterus 1	600.49	27.95	
	Utr85XU	Uterus 2	73.52	18.83	
	Utr135XO	Uterus 3	178.00	274.00	
10	Utr141XO	Uterus 4	289.00	26.00	
	CvxNKS54	Cervix 1	2.47	0.61	
	CvxKS83	Cervix 2	1.00	2.00	
	CvxNKS18	Cervix 3	1.00	0.00	
	CvxNK23	Cervix 4	5.84	14.47	
15	CvxNK24	Cervix 5	20.32	33.13	
	End68X	Endometrium 1	167.73	544.96	
	End8963	Endometrium 2	340.14	20.89	
	End8XA	Endometrium 3	1.68	224.41	
	End65RA	Endometrium 4	303.00	5.00	
20	End8911	Endometrium 5	1038.00	74.00	
	End3AX	Endometrium 6	6.59	1.69	
	End4XA	Endometrium 7	0.43	15.45	

- 22 -

	End5XA	Endometrium 8	17.81	388.02	
	End10479	Endometrium 9	1251.60	31.10	
	End12XA	Endometrium 10	312.80	33.80	
	Kid107XD	Kidney 1	2.68	29.65	
5	Kid109XD	Kidney 2	81.01	228.33	
	Kid10XD	Kidney 3	0.00	15.30	
	Kid6XD	Kidney 4	18.32	9.06	
	Kid11XD	Kidney 5	1.38	20.75	
10	Kid5XD	Kidney 6	30.27	0.19	
	Liv15XA	Liver 1	0.00	0.45	
	Liv42X	Liver 2	0.81	0.40	
	Liv94XA	Liver 3	12.00	2.16	
	Lng LC71	Lung 1	5.45	3.31	
15	LngAC39	Lung 2	1.11	0.00	
	LngBR94	Lung 3	4.50	0.00	
	LngSQ45	Lung 4	15.03	0.76	
	LngC20X	Lung 5	0.00	1.65	
	LngSQ56	Lung 6	91.77	8.03	
	ClnAS89	Colon 1	0.79	7.65	
20	ClnC9XR	Colon 2	0.03	0.00	
	ClnRC67	Colon 3	0.00	0.00	
	ClnSG36	Colon 4	0.81	0.35	
	ClnTX89	Colon 5	0.00	0.00	
	ClnSG45	Colon 6	0.00	0.06	
25	ClnTX01	Colon 7	0.00	0.00	
	Pan77X	Pancreas 1	0.89	2.62	
	Pan71XL	Pancreas 2	3.99	0.12	
	Pan82XP	Pancreas 3	59.92	28.44	
	Pan92X	Pancreas 4	17.21	0.00	

- 23 -

	StoAC93	Stomach 1	7.54	6.43	
	StoAC99	Stomach 2	19.49	3.19	
	StoAC44	Stomach 3	3.62	0.37	
	SmI21XA	Small Intestine 1	0.00	0.00	
5	SmIH89	Small Intestine 2	0.00	0.00	
	Bld32XK	Bladder 1	0.00	0.21	
	Bld46XK	Bladder 2	0.36	0.32	
	BldTR17	Bladder 3	0.28	0.00	
	Tst39X	Testis	11.24	2.24	
10	Pro84XB	Prostate 1	2.60	24.30	
	Pro90XB	Prostate 2	1.40	2.00	

0.00= Negative

Table 2 and Table 3 represent a combined total of 187 samples in 16 different tissue types. In the analysis of 15 matching samples, the higher levels of expression were in mammary gland, uterus, endometrium and ovary, showing a high degree of tissue specificity for the gynecologic tissues. Of all the samples different than those mentioned before analyzed, only a few samples (Kid109XD, LngSQ56, and Pan82XP) 20 showed high levels of expression of Ovr110.

Furthermore, the level of mRNA expression was compared in cancer samples and the isogenic normal adjacent tissue from the same individual. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of 25 mRNA expression in the cancer sample compared to the normal adjacent). Table 3 shows overexpression of Ovr110 in 15 of 16 mammary gland cancer tissues compared with their respective normal adjacent (mammary gland samples MamS516, MamS621, MamS854, Mam59X, MamS079, MamS967, MamB011X, MamS123, MamS699, 30 MamS997, Mam162X, MamA06X, Mam699F, Mam12X, and Mam42DN).

- 24 -

There was overexpression in the cancer tissue for 94% of the mammary gland matching samples tested.

For uterus, Ovr110 is overexpressed in 3 of 4 matching samples (uterus samples Utr23XU, Utr85XU, and Utr141XO). There 5 was overexpression in the cancer tissue for 75% of the uterus matching samples analyzed.

For endometrium, Ovr110 is overexpressed in 6 of 10 matching samples (endometrium samples End8963, End65RA, End8911, End3AX, End10479, and End12XA). There was 10 overexpression in the cancer tissue for 60% of the endometrium matching samples.

For ovary, Ovr110 shows overexpression in 1 of 1 matching sample. For the unmatched ovarian samples, 8 of 12 cancer samples show expression values of Ovr110 higher than 15 the median (2.52) for the normal unmatched ovarian samples. There was overexpression in the cancer tissue for 67% of the unmatched ovarian samples.

Altogether, the level of tissue specificity, plus the mRNA overexpression in most of the matching samples tested are 20 indicative of Ovr110 (including SEQ ID NO:1, 10, 11, 12 or 13) being a diagnostic marker for gynecologic cancers, specifically, mammary gland or breast, uterine, ovarian and endometrial cancer.

Measurement of Ovr114; Clone ID1649377; Gene ID 481154 (SEQ 25 ID NO:3)

The numbers depicted in Table 4 are relative levels of expression in 12 normal tissues of Ovr114 compared to pancreas (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue 30 from different individuals.

- 25 -

Table 4: Relative Levels of Ovr114 Expression in Pooled Samples

	Tissue	Normal
5	Colon	2.3
	Endometrium	7.6
	Kidney	0.5
	Liver	0.6
	Ovary	5.2
	Pancreas	1.0
10	Prostate	2.1
	Small Intestine	1.3
	Spleen	2.4
	Stomach	1.5
	Testis	15.8
15	Uterus	8.8

The relative levels of expression in Table 4 show that Ovr114 mRNA expression is detected in all the pools of normal tissues analyzed.

The tissues shown in Table 4 are pooled samples from 20 different individuals. The tissues shown in Table 5 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 4 cannot be directly compared to the values shown in Table 5.

The numbers depicted in Table 5 are relative levels of 25 expression of Ovr114 compared to pancreas (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

Table 5: Relative Levels of Ovrl14 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	17.04		3.93
Ovary 2	OvrG021SP1/SN2	Papillary serous adenocarcinoma	1.62		4.34
5	OvrG010SP/SN	Papillary serous adenocarcinoma	0.50		1.12
Ovary 4	Ovra081F/A082D	Mucinous tumor, low malignant potential		0.84	0.96
Ovary 5	Ovra084/A086	Mucinous tumor, grade G-B, borderline		5.24	6.00
Ovary 6	Ovr14604A1C	Serous cystadenofibroma, low malignancy		5.33	
Ovary 7	Ovr14638A1C	Follicular cysts, low malignant potential		8.11	
10	Ovr10400	Papillary serous adenocarcinoma, G2	13.27		
Ovary 9	Ovr11570	Papillary serous adenocarcinoma	106.08		
Ovary 10	Ovr10050	Papillary serous endometriocarcinoma	77.04		
Ovary 11	Ovr10280	Ovarian carcinoma	14.78		
Ovary 12	Ovr14603A1D	Adenocarcinoma	22.23		

- 27 -

Ovary 13	Ovr9410C360	Endometrioid adenocarcinoma	4.74	
Ovary 14	Ovr1305X	Papillary serous adenocarcinoma	96.49	
Ovary 15	Ovr7730	Papillary serous adenocarcinoma	8.40	
Ovary 16	Ovr988Z	Papillary serous adenocarcinoma	6.40	
5 Ovary 17	Ovr9702C018GA	Normal Cystic	12.06	
Ovary 18	Ovr2061	Normal left atrophic, small cystic	10.11	
Ovary 19	Ovr9702C020GA	Normal-multiple ovarian cysts	12.70	
Ovary 20	Ovr9702C025GA	Normal-hemorrhage CL cysts	22.09	
Ovary 21	Ovr9701C050GB	Normal-multiple ovarian cysts	9.01	
10 Ovary 22	Ovr9701C087RA	Normal-small follicle cysts	1.86	
Ovary 23	Ovr9702C032RA		7.81	
Ovary 24	Ovr9701C109RA	Normal	1.50	
Ovary 25	Ovr9411C057R	Benign large endometriotic cyst	5.22	
Ovary 26	Ovr9701C179a	Normal	3.09	
15 Ovary 27	Ovr1461O	Serous cystadenofibroma, no malignancy	3.53	
Ovary 28	Ovr9701C035GA	Normal	6.32	

- 28 -

	Ovary 29	Ovr9702C007RA	Normal			0
	Ovary 30	Ovr9701C087RA	Normal-small follicle cysts			1.97
	Ovary 31	Ovr9411C109	Normal			9.49
	Ovary 32	Ovr9701C177a	Normal-cystic follicles			3.85
5	Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	1.30		0.70
	Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	1.83		11.90
	Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	13.32		7.76
	Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	3.62		3.34
10	Mammary Gland 1	Mam00042D01/N01		3.13		0.76
	Mammary Gland 2	MamS99-522A/B		4.45		0.45
	Mammary Gland 3	Mam1620F/1621F		0.74		1.91
15	Mammary Gland 4	Mam4003259a/g		3.48		2.00
	Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	46.96		11.96
	Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	20.02		5.90
	Uterus 3	Utr13590/13580	Tumor/NAT	10.23		7.74
20	Uterus 4	Utr14170/14180	Malignant tumor/NAT	7.52		4.92

- 29 -

	Cervix 1	CvxVNMM00083/83	Keratinizing squamous cell carcinoma	5.47		14.31
	Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	4.99		3.99
	Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	10.14		14.22
	Bladder 1	Bld665T/664T		1.43		4.03
5	Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	1.15		0.99
	Kidney 1	Kid4003710C/F		0.03		0.35
	Kidney 2	Kid1242D/1243D		1.61		0.14
	Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	2.44		5.73
	Lung 2	Lng8890A/8890B	Cancer/NAT	1.11		5.19
10	Lung 3	Lng9502C109R/10R		1.99		0.80
	Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.67		1.07
	Liver 2	LivVNMM00175/175	Cancer/NAT	15.46		2.85
	Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	2.83		0.70
	Skin 2	Skn4005287A1/B2		0.91		4.02
15	Small Int. 1	Sml9802H008/009		0.87		0.82
	Stomach 1	Sto4004864A4/B4	Adenocarcinoma /NAT	0.81		1.22
	Stomach 2	StoS9822539A/B	Adenocarcinoma /NAT	1.22		1.39

10

15

	Stomach 3	StoS99728A/C	Malignant gastrointestinal stromal tumor	0.47		0.35
	Prostate 1	Pro1012B/1013B	Adenocarcinoma /NAT	2.39		2.61
	Prostate 2	Pro1094B/1095B		0.10		0.38
	Pancreas 1	Pan776p/777p	Tumor/NAT	2.39		0.52
5	Pancreas 2	Pan824p/825p	Cystic adenoma	1.66		1.22
	Testis 1	Tst239X/240X	Tumor/NAT	1.24		1.72
	Colon 1	Cln9706c068ra/69ra	Adenocarcinoma /NAT	0.38		0.65
	Colon 2	Cln4004732A7/B6	Adenocarcinoma /NAT	0.44		1.26
	Colon 3	Cln4004695A9/B8		1.94		1.53
10	Colon 4	Cln9612B006/005	Asc. Colon, Cecum, adenocarcinoma	3.38		1.10
	Colon 5	Cln9704C024R/25R	Adenocarcinoma /NAT	1.66		2.77

- 31 -

Table 4 and Table 5 represent a combined total of 129 samples in 17 human tissue types. Among 117 samples in Table 5 representing 16 different tissues high levels of expression are seen only in ovarian cancer samples. The median 5 expression of Ovr114 is 14.03 (range: 0.5 - 106.08) in ovarian cancer and 4.34 (range: 0 - 22.09) in normal ovaries. In other words, the median expression levels of Ovr114 in cancer samples is increased 3.5 fold as compared with that of the normal ovarian samples. Five of 12 ovarian cancers (42%) 10 showed increased expression relative to normal ovary (with 95% specificity). The median expression of Ovr114 in other gynecologic cancers is 4.99, and 2 out of 15 samples showed expression levels comparable with that in ovarian cancer. The median of the expression levels of Ovr114 in the rest of the 15 cancer samples is 1.24, which is more than 11 fold less than that detected in ovarian cancer samples. No individual showed an expression level comparable to that of ovarian cancer samples (except Liver 2; LivVNM00175/175).

The 3.5 fold increase in expression in 42% of the 20 individual ovarian cancer samples and no compatible expression in other non-gynecologic cancers is indicative of Ovr114 being a diagnostic marker for detection of ovarian cancer cells. It is believed that the Ovr114 marker may also be useful in detection of additional gynecologic cancers.

25 **Measurement of Ovr115; Clone ID1283171; Gene ID 332459 (SEQ
ID NO:2 or 14)**

The numbers depicted in Table 6 are relative levels of expression Ovr115 compared to their respective calibrators. The numbers are relative levels of expression in 12 normal 30 tissues of ovaries compared to Testis (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

- 32 -

Table 6: Relative Levels of Ovr115 Expression in Pooled Samples

	Tissue	Normal
5	Colon	858.10
	Endometrium	12.34
	Kidney	3.76
	Liver	0.00
	Ovary	0.43
	Pancreas	0.00
10	Prostate	8.91
	Small Intestine	62.25
	Spleen	0.00
	Stomach	37.53
	Testis	1.00
15	Uterus	47.67

The relative levels of expression in Table 6 show that Ovr115 mRNA expression is detected in all the 12 normal tissue pools analyzed.

The tissues shown in Table 6 are pooled samples from 20 different individuals. The tissues shown in Table 7 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 6 cannot be directly compared to the values shown in Table 7.

The numbers depicted in Table 7 are relative levels 25 of expression of Ovr115 compared to testis (calibrator), in 46 pairs of matching samples and 27 unmatched tissue samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In cancers (for example, 30 ovary) where it was not possible to obtain normal adjacent samples from the same individual, samples from a different normal individual were analyzed.

- 33 -

Table 7: Relative Levels of Ovr115 Expression in Individual Samples

Tissue	Sample ID	Cancer Type	Cancer	Borderline Malignant	Normal & Matching Normal Adjacent
Ovary 1	Ovr10370/10380	Papillary serous adenocarcinoma, G3	193.34		0.24
Ovary 3	OvrG021SP1/SN2	Papillary serous adenocarcinoma	0.38		0.31
5	OvrG010SP/SN	Papillary serous adenocarcinoma	231.25		0.45
Ovary 2	OvrA084/A086	Mucinous tumor, grade G-B, borderline	143.34		16.65
Ovary 5	OvrA081F/A082D	Mucinous tumor, low malignant potential	314.13		0
Ovary 19	Ovr14604A1C	Serous cystadenofibroma, low malignancy	299.87		
Ovary 26	Ovr14638A1C	Follicular cysts, low malignant potential	1278.32		
Ovary 6	Ovr10400	Papillary serous adenocarcinoma, G2	144.25		
Ovary 22	Ovr9410C360	Endometrioid adenocarcinoma	0.29		
Ovary 23	Ovr1305X	Papillary serous adenocarcinoma	157.41		
Ovary 27	Ovr7730	Papillary serous adenocarcinoma	340.04		
Ovary 28	Ovr988Z	Papillary serous adenocarcinoma	464.75		

- 34 -

Ovary 7	Ovr1157O	Papillary serous adenocarcinoma	432.07
Ovary 8	Ovr1005O	Papillary serous endometriocarcinoma	74.23
Ovary 9	Ovr1028O	Ovarian carcinoma	1408.79
Ovary 10	Ovr14603A1D	Adenocarcinoma	0.00
5	Ovr9702C018GA	Normal Cystic	0.16
Ovary 11	Ovr2061	Normal left atrophic, small cystic	0.00
Ovary 12	Ovr9702C020GA	Normal-multiple ovarian cysts	0.00
Ovary 13	Ovr9702C025GA	Normal-hemorrhage CL cysts	0.00
Ovary 14	Ovr9701C050GB	Normal-multiple ovarian cysts	0.91
Ovary 15	Ovr9701C087RA	Normal-small follicle cysts	0.00
Ovary 16	Ovr9702C032RA		0.28
Ovary 17	Ovr9701C109RA	Normal	0.00
Ovary 18	Ovr9411C057R	Benign large endometriotic cyst	38.87
Ovary 20	Ovr9701C179a	Normal	0.08
Ovary 21	Ovr1461O	Serous cystadenofibroma, no malignancy	0.00
15	Ovr9701C035GA	Normal	0.00
Ovary 24	Ovr9702C007RA	Normal	0.00
Ovary 25	Ovr9702C007RA		
Ovary 29			

	Ovary 30	Ovr9701C087RA	Normal-small follicle cysts		0.00
	Ovary 31	Ovr9411C109	Normal		0.00
	Ovary 32	Ovr9701C177a	Normal-cystic follicles		0.00
5	Uterus 1	Utr850U/851U	Stage 1 endometrial cancer/NAT	39.95	13.60
	Uterus 2	Utr233U96/234U96	Adenocarcinoma/NAT	140.37	22.67
	Uterus 3	Utr13590/1358)	Tumor/NAT	16.45	32.50
	Uterus 4	Utr14170/14180	Malignant tumor/NAT	288.52	5.29
	Endometrium 1	End14863A1A/A2A	Moderately differ. Endome. carcinoma/NAT	2.61	6.24
	Endometrium 2	End9709C056A/55A	Endometrial adenocarcinoma/NAT	2.10	49.40
10	Endometrium 3	End9704C281A/2A	Endometrial adenocarcinoma/NAT	480.77	19.22
	Endometrium 4	End9705A125A/6A	Endometrial adenocarcinoma/NAT	322.07	31.08
	Lung 1	Lng750C/751C	Metastatic osteogenic sarcoma/NAT	38.81	7.36
	Lung 2	Lng8890A/8890B	Cancer/NAT	690.12	14.71
	Lung 3	Lng9502C109R/10R		1756.90	2.86
15	Skin 1	Skn2S9821248A/B	Secondary malignant melanoma	10.56	0.00
	Skin 2	Skn4005287A1/B2		331.30	47.23
	Prostate 1	Pro1012B/1013B	Adenocarcinoma/NAT	14.64	4.39

- 36 -

	Prostate 2	Pro1094B/1095B		0.09		2.54
	Bladder 1	Bld665T/664T		404.56		90.20
	Bladder 2	Bld327K/328K	Papillary transitional cell carcinoma/NAT	77.35		177.37
	Kidney 1	Kid4003710C/F		0.17		12.72
5	Kidney 2	Kid1242D/1243D		0.00		13.74
	Mammary Gland 1	Mam1620F/1621F		0.27		0.12
	Mammary Gland 2	Mam4003259a/g		5.71		0.00
10	Liver 1	Liv1747/1743	Hepatocellular carcinoma/NAT	0.14		0.69
	Liver 2	LivVNM00175/175	Cancer/NAT	0.00		0.00
	Small Int. 1	Sml9802H008/009		128.44		151.38
	Stomach 1	Sto4004864A4/B4	Adenocarcinoma/NAT	303.01		116.72
	Stomach 2	Stos9822539A/B	Adenocarcinoma/NAT	24.12		17.76
15	Stomach 3	Stos99728A/C	Malignant gastrointestinal stromal tumor	0.00		9.10
	Pancreas 1	Pan776p/777p	Tumor/NAT	0.00		0.43
	Pancreas 2	Pan824p/825p	Cystic adenoma	0.00		3.17
	Testis 1	Tst239X/240X	Tumor/NAT	24.05		1.37
	Colon 1	Cln9706c068ra/69ra	Adenocarcinoma/NAT	605.60		169.77
20	Colon 2	Cln4004732A7/B6	Adenocarcinoma/NAT	367.20		281.32

- 37 -

Colon 3	Cln4004695A9/B8		316.15		295.77
Colon 4	Cln9612B006/005	Asc. Colon. Cecum, adenocarcinoma	820.89		543.52
Colon 5	Cln9704C024R/25R	Adenocarcinoma/NAT	161.18		150.07
Cervix 1	CvxVNMC00083/83	Keratinizing squamous cell carcinoma	738.17		1195.88
5 Cervix 2	CvxIND00023D/N	Large cell nonkeratinizing carcinoma	1473.04		1229.80
Cervix 3	CvxIND00024D/N	Large cell nonkeratinizing carcinoma	2877.48		1275.02

- 38 -

Table 6 and Table 7 represent a combined total of 129 samples in 17 human tissue types. Comparisons of the level of mRNA expression in ovarian cancer samples and the normal adjacent tissue from the same individuals or normal tissues from other 5 individuals are shown in Table 7. Ovr115 was expressed at higher levels in 9 of 12 cancer tissues (75%), relative to the maximum level detected in all 21 normal or normal adjacent ovarian samples. All 4 of 4 (100%) ovarian tumors with borderline malignancy had elevated Ovr115 expression. The 10 median expression in ovarian cancers (including the ones with borderline malignancy) was 212.30 while the median expression in normal ovaries was 0. When compared with their own normal adjacent tissue samples, expression levels of Ovr115 were also elevated in 3 of 3 (100%) lung cancers, 3 of 4 (75%) 15 uterus cancers and 2 of 4 (50%) endometrial cancers.

The relatively high expression levels of Ovr115 in ovarian and other selected cancer samples is indicative of Ovr115 being a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer.

20 A homolog of Ovr115 has also been identified in public data base; g2597613 as gi|2507612|gb|U75329.1|HSU75329 Human serine protease mRNA, complete CDS. This homolog is depicted herein as SEQ ID NO:9. It is believed that SEQ ID NO:9 or the protein encoded thereby (SEQ ID NO:15) may also 25 be useful as a diagnostic marker for detection of ovarian, lung, uterine and endometrial cancer in human patients.

- 39 -

What is claimed is:

1. A method for diagnosing the presence of a selected cancer in a patient comprising:
 - (a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and
 - 5 (b) comparing the measured levels of CSG with levels of CSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CSG in said patient versus normal human control is associated with the presence of a selected cancer.
- 10 2. A method of diagnosing metastases of a selected cancer in a patient comprising:
 - (a) identifying a patient having a selected cancer that is not known to have metastasized;
 - (b) measuring CSG levels in a sample of cells, tissues,
15 or bodily fluid from said patient; and
 - (c) comparing the measured CSG levels with levels of CSG in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in the patient versus the normal human control is associated with a cancer
20 which has metastasized.
3. A method of staging a selected cancer in a patient having the selected cancer comprising:
 - (a) identifying a patient having the selected cancer;
 - (b) measuring CSG levels in a sample of cells, tissue,
25 or bodily fluid from said patient; and
 - (c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control sample, wherein an increase in measured CSG levels in said patient versus the normal human control is associated with a
30 cancer which is progressing and a decrease in the measured CSG levels is associated with a cancer which is regressing or in remission.

- 40 -

4. A method of monitoring a selected cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having a selected cancer that is not known to have metastasized;

5 (b) periodically measuring levels of CSG in samples of cells, tissues, or bodily fluid from said patient for CSG; and

10 (c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of a selected cancer in a patient comprising:

15 (a) identifying a patient having a selected cancer;

(b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient for CSG; and

20 (c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

25 6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 10, 11, 12 or 13 and the selected cancer is a gynecologic cancer selected from the group consisting of breast, ovarian, endometrial and uterine cancer.

30 7. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:2, 9 or 14 and the selected cancer is lung cancer or a gynecologic cancer selected from the group consisting of ovarian, endometrial and uterine cancer.

- 41 -

8. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14 and the selected cancer is ovarian cancer.

9. An antibody against a CSG wherein said CSG comprises SEQ ID NO:1, 2, 3, 9, 10, 11, 12, 13 or 14.

5 10. A method of imaging a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

11. The method of claim 10 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

10 12. A method of treating a selected cancer in a patient comprising administering to the patient an antibody of claim 9.

13. The method of claim 12 wherein the antibody is conjugated to a cytotoxic agent.

SEQUENCE LISTING

<110> Salceda, Susana
Sun, Yongming
Recipon, Herve
Cafferkey, Robert
DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING VARIOUS CANCERS

<130> DEX-0043

<140>
<141>

<150> 60/098,880
<151> 1998-09-02

<160> 15

<170> PatentIn Ver. 2.0

<210> 1
<211> 2587
<212> DNA
<213> Homo sapiens

<400> 1
ggaggcagc gggcagctcc actcagccag taccagata cgctggAAC cttccccAGC 60
catggcttcc ctggggcaga tcctttctg gagcataatt agcatcatca ttattctggc 120
tggagcaatt gcactcatca ttggcttgg tatttcaggg agacactcca tcacagtac 180
tactgtcgcc tcagctggga acattgggg aatatggaaatc ctgagctgca cttttgaacc 240
tgacatcaa ctttctgata tcgtgataca atggctgaag gaagggttt taggcttgg 300
ccatgagttc aaagaaggca aagatgagct gtcggagcag gatgaaaatgt tcagaggccg 360
gacagcagtg tttgtgtatc aagtgtatgt tggcaatgcc tctttgcggc tgaaaaacgt 420
gcaactcaca gatgctggca cctacaaatg ttatatcatc acttctaaag gcaaggggaa 480
tgctaacctt gagtataaaa ctggagcctt cagcatgccg gaagtgaatg tggactataa 540
tgccagctca gagacattgc ggtgtgaggc tccccgatgg ttccccccAGC ccacagtgg 600
ctgggcattcc caagttgacc agggagccaa cttctcgaa gtctccaata ccagctttga 660
gctgaactct gagaatgtga ccatgaaggt tgtgtctgtg ctctacaatg ttacgatcaa 720
caacacatac tcctgtatga ttgaaaatga cattGCCAAA gcaacagggg atatcaaagt 780
gacagaatcg gagatcaaaa ggccggagtc cctacagctg ctaaactcaa aggcttctct 840
gtgtgtctct tctttctttg ccatcagctg ggcacttctg cctctcagcc cttacctgat 900
gctaaaataa tggccttgg ccacaaaaaa gcatgcaaaag tcattgttac aacaggggatc 960
tacagaacta tttcaccacc agatatgacc tagttttata tttctggag gaaatgaatt 1020
catatctaga agtctggagt gagcaaacaa gagcaagaaa caaaaagaag ccaaagcag 1080
aaggctccaa tatgaacaag ataaatctat cttcaaaagac atattagaag ttggaaaaat 1140

aattcatgtg aactagacaa gtgtgttaag agtgataagt aaaatgcacg tggagacaag 1200
 tgcatccca gatctcaggc acctccccc gcctgtcacc tggggagtga gaggacagga 1260
 tagtgcgtgt tctttgtctc tgaatttta gttatatgtg ctgtaatgtt gctctgagga 1320
 agcccctgga aagtcttatcc caacatatcc acatcttata ttccacaaaat taagctgttag 1380
 tatgtaccct aagacgctgc taattgactg ccacttcgca actcaggggc ggctgcattt 1440
 tagtaatggg tcaaattgtt cacttttat gatgcttcca aaggtgcctt ggcttctt 1500
 cccaaactgac aaatgcacaa gttgagaaaa atgatcataa ttttagcata aacagagcag 1560
 tcggcgacac cgatttata aataaaactga gcacccctt ttaaacaaaa caaatgcggg 1620
 tttatccctc agatgtatgtt catccgtgaa tggccaggaa aaggacctt caccttgact 1680
 atatggcatt atgtcatcac aagctctgag gcttctcctt tccatctgc gtggacagct 1740
 aagacccatg tttcaatag catctagagc agtggactc agctgggggtt atttcgcccc 1800
 ccatctccgg gggaaatgtct gaagacaatt ttgggtacccatgagggg gtggaggagg 1860
 atacagtgct actaccaact agtggataaa ggcaggatg gctgtcaac ctcctaccat 1920
 gtacaggacg tctcccccatt acaactaccc aatccgaatgtcaactgtg tcaggactaa 1980
 gaaaccctgg ttttagtagt aaaaaggccct gggaaagaggg gagccaaacaa atctgtctgc 2040
 ttctcacatt agtcatggc aaataagcat tctgtctt tggctgtgc ctcagcacag 2100
 agagccagaa ctctatcggg caccaggata acatctctca gtgaacagag ttgacaaggc 2160
 ctatggaaaa tgcctgatgg gattatcttcc agcttgttga gtttctaagt ttcttccct 2220
 tcattctacc ctgcagccaa agttctgtaa gagaatgcc tggatcttag ctcaggtttt 2280
 cttactctga atttagatct ccagaccctt cctggccaca attcaaattt aggcaacaaa 2340
 catatacctt ccatgaagca cacacagact tttgaaagca aggacaatgtg ctgcttgaat 2400
 tgaggcccttgg aggaatgaag ctttgaagga aaagaataact ttgtttccag ccccccctccc 2460
 acactcttca tgtgttaacc actgccttcc tggaccccttgg agccacgggtt actgtattac 2520
 atgttgttat agaaaactga ttttagagtt ctgatcggtt aagagaatgtg taaaatatac 2580
 atttcctt 2587

<210> 2
<211> 2070
<212> DNA
<213> Homo sapiens

<400> 2
 cacagagaga ggcagcagct tgctcagccg acaaggatgc tgggcgtgag ggaccaaggc 60
 ctggccctgca ctggggcctc ctccagccag tgctgaccag ggacttctga cctgctggcc 120
 agccaggacc tgggtggggg ggcctcttg ctgccttggg gtgacaatct cagctccagg 180
 ctacaggagg accgggagga tcacagagcc agcatgttac aggatcctga cagtgtatcaa 240
 cctctgaaca gcctcgatgt caaacccttg cgcaaaacccc gtatcccat ggagaccccttc 300
 agaaagtgg ggatcccat catcatagca ctactgagcc tggcgagtagt catcattgtg 360
 gttgtcctca tcaaggtgt tctggataaa tactacttcc tctgcgggca gcctctccac 420
 ttcatcccga ggaaggcagct gtgtgacgga gagctggact gtccttggg ggaggacgag 480
 gagcactgtg tcaagagctt ccccgaaaggc cctgcagttt cagtcggcct ctccaaaggac 540
 cgatccacac tgcaggtgtt ggactcgcc acagggaaact ggttctctgc ctgtttcgac 600
 aacttcacag aagctctcgc tgagacagcc tggtaggcaga tggctacag cagcaaacccc 660
 actttcagag ctgtggagat tggcccaagac caggatctgg atgttgttga aatcacagaa 720
 aacagccagg agcttcgcat gcggaaactca agtggggccct gtctctcagg ctccctggc 780
 tccctgcact gtcttgcctg tggaaagagc ctgaagaccc cccgtgtgtt ggggtggggag 840
 gaggccctctg tggattcttgc gcttggcag gtcagcatcc agtacgacaa acagcacgtc 900
 tgtggaggaga gcatcctgga ccccaactgg gtcctcacgg gcagcccaact gcttcaggaa 960

acataccat gtgttcaact ggaagggtgcg ggcaggctca gacaaactgg gcagcttccc 1020
 atccctggct gtggccaaga tcatcatcat tgaattcaac cccatgtacc ccaaagacaa 1080
 tgacatcgcc ctcatgaagc tgcagttccc actcaacttc tcagggcacag tcagggccat 1140
 ctgtctgccc ttcttgatg aggagctcac tccagccacc ccactctgga tcattggatg 1200
 gggcttacg aagcagaatg gagggaaagat gtctgacata ctgctgcagg cgtcagtcca 1260
 ggtcattgac agcacacggt gcaatgcaga cgatgcgtac cagggggaaag tcaccgagaa 1320
 gatgatgtgt gcagggatcc cggaaaggggg tgtggacacc tgccaggggt acagtggtgg 1380
 gccccctgatg taccaatctg accagtggca tgtgtggc atcgttagct ggggctatgg 1440
 ctgcggggc cccgagcaccc caggagtata caccaaggtc tcagcctatc tcaactggat 1500
 ctacaatgtc tggaaaggctg agctgtaatg ctgctgcccc tttgcagtgc tgggagccgc 1560
 ttccttcctg ccctgcccac ctggggatcc cccaaagtca gacacagagc aagagtcccc 1620
 ttgggtacac ccctctgccc acagcctcag catttcttgg agcagcaaag ggcctaatt 1680
 cctataaagag accctcgcag cccagaggcg cccagaggaa gtcagcagcc ctagctcggc 1740
 cacacttggt gctcccagca tcccagggag agacacagcc cactgaacaa ggtctcaggg 1800
 gtattgtcaa gccaagaagg aactttccca cactactgaa tggaaaggcgg ctgtcttgc 1860
 aaagcccaga tcaactgtggg ctggagagga gaagaaaagg gtctgcgccca gcccgtccg 1920
 tcttcaccca tccccaaagcc tactagagca agaaaccagt tgtaatataa aatgcactgc 1980
 cctactgttg gtatgactac cgttacctac tggtgcattg ttattacagc tatggccact 2040
 attattaaag agctgtgtaa catctctggc 2070

<210> 3
 <211> 1709
 <212> DNA
 <213> Homo sapiens

<400> 3

agcagactca caccagaact acattccctg gccccctgcc tggccaggcc 60
 ttgggtggca agtctgaccc gagaaaagga tctgcagaaa atcagactat gggatcactt 120
 tgtttgcata ttggaaatga cattcttcc caccccgagga aaaccccttgg gactttcaga 180
 gacatttgttgg ctagccaaacc acatggtcag cctccaaagtt gagaggctca gtaaccctcc 240
 tatcccttaga gaattccaaa gtgtggatgt aatttaacta gaaagccatt ggtgactatc 300
 tgtgatcctc tggaaagtatg ctatgttg tatacttgc atccaaagcc agagggaaacc 360
 acaatgacta gtaaaacgggt ggtctcaatg cccacttagc ctctgcctc gaatttgacc 420
 atagtggcgt tcagctgata gagcggaaag aagaaaatatg catttttat gaaaaaaataa 480
 atatccaaaga gaagatgaaa ctaaatggag aaattgaaaat acatctactg gaagaaaaga 540
 tccaattcct gaaaatgaag attgctgaga agcaaaagaca aattttgtgtg acccagaaat 600
 tactgcccagc caagagggtcc ctggatgccg acctagctgt gctccaaatt cagtttcac 660
 agtgtacaga cagaattaaa gacctggaga aacagttcgt aaagcctgtat ggtgagaata 720
 gagctcgctt ccttccaggaa aaagatctga ccgaaaaaaga aatgatccaa aaatttagaca 780
 agctggaact acaactggcc aagaaggagg agaagctgt ggagaaggat ttcatctatg 840
 agcaggtctc caggctcaca gacaggctct gcagcaaaac tcagggctgc aagcaggaca 900
 cactgctctt agccaagaag atgaatggct atcaaagaag gatcaaaaat gcaactgaga 960
 aaatgatggc tcttgttgc gagctgtcca tgaaacaagc cctaaccatt gaactccaaa 1020
 aggaagtctcgg gggaaaagaa gacttcatct tcacttgcaat ttccaggata gaaaaaggc 1080
 tgccactcaa taaggaaatt gagaagaat ggttggaaatg ctttcgagat gaagaaaatgc 1140
 acgccttggc catcgctgaa aagtctcagg agttcttggc agcagataat cgccagctgc 1200
 ccaatgggtt ttagacacaact gcagagcagc gtccgaatgc ctacatccca gaagcagatg 1260
 ccactcttcc tttgccaaaaa ctttatggtg ctttgctcc ttttaaaccc agtgaacctg 1320

gagccaatat gaggcacata aggaaacctg ttataaagcc agttgaaatc tgaatatgtg 1380
aacaaatcca ggcctctcaa ggaaaagact tcaaccaggc ttccctgtac ccacaggtga 1440
aaaatgtgag cataatactt ctaatattat tgataagtaa ggttaaccaca attagtgc 1500
aacagagtac aacagggttt ctattnacc accaactact ataccttca tgacggtgaa 1560
tgggacatag aactgtccta catttatgtc aaagtatata tttgaatcgc ttatatttc 1620
ttttcactc ttatattgtg gtacattcca gaaatttgta gtaggcaagg tgctataaaa 1680
atgcactaaa aataaatctg ttctcaatg 1709

<210> 4

<211> 257

<212> DNA

<213> Homo sapiens

<400> 4

ttaatggta agtattttt atatgctta gctatagcta aagaaaaactg atacttaaca 60
aagttgata gtattattca ctgggtctcc taaaatattg ttttcagtg taaaatatgc 120
atatctctca tatttaatat gaaagtcttg aaatgtatca gacagaaggg gatttcagtt 180
tgcaaataat gagcaatgta gcaattttaa cacattcat aaatataatat tttgtcattg 240
gtggagagca ccatttg 257

<210> 5

<211> 359

<212> DNA

<213> Homo sapiens

<400> 5

gcctgagagc acttagcggt catgagtgtc cccaccatgg cctggatgat gcttcctc 60
ggactccttg cttatggatc aggtcaggga gtggattctc agactgtggt gacccaagag 120
ccatcggtat cagtgcccc tggagggaca gtcacactca cttgtggctt ggccctgtac 180
tcagtcctca ctaatttctt ccccacctgg taccagcaga ccccaggcca ggctccacgc 240
acgctcatct acagcacaag cactcgctct tctgggtcc ctgatcggtt ctctggctcc 300
atccttggga acaaagctgc cctcaccatt acgggggccc aggcagatga tgaatctga 359

<210> 6

<211> 1372

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (6)

<220>

<221> unsure

<222> (9)

<400> 6

ccttanagnnc ttgggtgcc aacagaatgc ccatatccgt cttacttgtg aggaagctt 60

ccttgggcgc cctctgctgg ccctcctgaa gctaacaggg gcgagtgctc ggtggttac 120
 aaattgcctc catgcagact atgaaactgt tcagcctgtat atagtttagat ctctggcact 180
 ggcgcaggag gtcttcaga tttgcagatc aaggagaacc caggagttc aaagaagcgg 240
 ctagtaaagg tctctgagat ctttcacta gctacatcct cagggttagga ggaagatggc 300
 ttccagaaggc atgcggctgc tccttattgt gagtcgcctg gccaacacag gagtcctggg 360
 tgatatacatc atgagaccca gctgtgcctc tgggatggtt ttaccacaag tccaaattgct 420
 atggttactt caggaagctg aggaactggc ctgtgcctg gctcgagtgt cagtcttacg 480
 gaaacggagc ccacctggca tctatcctgaa gtttaaagga agccagcacc atagcagagt 540
 acataagtgg ctatcagaga agccagccga tatggattgg cctgcacgac ccacagaaga 600
 ggcagcagtgcagtg gcatggatt gatggggcca tgttatctgta cagatcctgg tctggcaagt 660
 ccatgggtgg gaacaagcac tgcgtgata tgagctccaa taacaacttt ttaacttgg 720
 gcagcaacga atgcaacaag cgccaaacact tcctgtgca gtaaccgacca tagagaaga 780
 atcaagattc tgcttaactcc tgcacagccc cgtcctcttc ctttctgcta gcctggctaa 840
 atctgctcat tatttcagag gggaaaccta gcaaactaag agtgataagg gcccctactac 900
 actggctttt ttaggcttag agacagaaaac tttacgttgc gcccagttagt ggcttctagc 960
 tctaaatgtt tgccccgcca tccctttcca cagtatcctt cttccctctt cccctgtctc 1020
 tggctgtctc gagcagtcta gaagagtgc tctccagcct atgaaacagc tgggtctttg 1080
 gccataagaa gtaaaagattt gaagacagaa ggaagaaaact caggagtaag cttctagccc 1140
 ctttcagctt ctacaccctt ctgcctctc tccattgcct gcaccccccacc ccagccactc 1200
 aactcctgct tggccatgg gaaggtttac cagtagaaatc cttgtcttaggt 1260
 tgcgtggc catacattcc ttaataaaac cattgtgtac ataagaggtt gctgtgttcc 1320
 agttcagtaa atggtaatg tggaaaatgt aaataagacc aagaaataca aa 1372

<210> 7
<211> 291
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (277)

<400> 7
agaatggtag tagtaagaag aagaaaaata gaggatctga atgtatTTT aaggttagagt 60
ccactggact tagagatggta ttgaatgtgg aagattaagg aaaggagaa atgaaagata 120
gtcttaggtt tcataccttcag atgactgggt gaacagcagt gttctttgtt aagatgggaa 180
agacttagggaa aaagagccag ttctgtattt agcatattat attaaagaca atcccatctg 240
ggtccaaaga caatgttgc ttttttctt agatacgttgc ctttagacc t 291

<210> 8
<211> 1275
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (410)

<220>
 <221> unsure
 <222> (728)..(756)

<220>
 <221> unsure
 <222> (957)

<400> 8

```

attctagaac atatgtataa gctaaaaaca gtatTTTact cagatcagta gttatcgTgt 60
ctatcagcta taaaaaaaaat caactgccag ccaagaactt taaaacttta agctgtgtat 120
tatagaaccg ttttGTgtAG cattGGAATA ttGTCcATT tGtaAGtcat tGtGAATGTT 180
cttaattatc agCTTGAAGG tATTTTGTA tAAAAGTTG acATTGAAGA acCTTAAGTGG 240
atGATGGGAT ttGGGGCCAG tagtGAAAGt atGTTTcCtc tAAAATATTt ccCTAAACAG 300
tggTatacat ggTTTATTtA ttatGAGATT tGtATATGTT ctGtGTTTct ctGtGAACAA 360
tGTTTcAGtC tCTCTGTcAc catatGTAAG gggAAAGTCCA caAAATATAGn actACATTGc 420
acaAAAactAA aattGTTAAT tacaAGAAAA tataGGTGT tacCTTTGA aggTTTtAtA 480
atacaTATGG ttGTcACAAT acGTatATAT gataAAatGGt gtACATATAc agatGTTTAt 540
ggTGTATAAA ttTTTcATAA cccAAATTAGA attATCTTcC tgATTCTTA ttCAATAACA 600
tgCTTAATTCC tCTTCTATGT tCTTATAGTGA cagaATGCTA acTTTCTTA tACCCTGGCA 660
gaggACAGAG gagTCTGGTC taggATGGGG aACTGAATTt tGtACGAAA aggAAAGAGA 720
aaggATGNNN nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnaAt tGTTCTTAGt cATTtTGATT 780
ggCCATTGTA acAGTCTACA agTTAACGT tATTTCCAGt gaAGTAGGAT ggCTGACCTA 840
gCAATACATG tTTCTTCAAAG aggGTAAACA tGCTTGTAGt acCTAAAGGT aaATTTGTA 900
cATTGACAT cAGGGGTGTT ataAGTACTG cACTTAATAc AAAGCTATTt CTCAATNGTg 960
ttATTTTGA gacaAAATTt tCTTcACCAT taACTTCTG ttGGTAGCTt tttGTTTGT 1020
aaaaATTGAG agATGGCAAT gCTTATCTCA accAGATTAT cCATCTGCAg aAtTAAGGTA 1080
tgCAACTGGT AAATAAAAGA caAAATGCTC AGTTTGTCTT tCTCAACCTT tgAGTTCTTA 1140
acCTTGTAGT tAAAACCTAG tCTAAATAAGT gggAAATGTCT tGGTTTACAG tAAAGTTTC 1200
ttGGGAAGGA tCTTGGTTT gtGATCTATT tGtGAATTAA ggAGTAGATG tTAACCATTa 1260
ttttATAGAT aagtG 1275

```

<210> 9
 <211> 2479
 <212> DNA
 <213> Homo sapiens

<400> 9

```

gtCATATTGA acATTCCAGA tacCTATCAT tactCGATGC tGTTGATAAC agCAAGATGG 60
ctttGAACtC aggTCACCA ccAGCTATTG gACCTACTA tGAAAACCAT ggATAACCAAC 120
cgGAAAACCC CTA TCCCgCA cAGCCCACtG tGGTCCCCAC tGTCTACGAG gtGcATCCG 180
ctCAGTACTA cCCGTCcccCtG tGCCCCAGt acGCCCCGAG gGTCTGACG cAGGCTTCCA 240
acCCCGTGTt CTGACGCAg cCCAAATCCC cAtCCGGAC aGTGTGcAcc tCAAAGACTA 300
agAAAGCACT gtGcATCACC ttGACCCtG ggACCTtCCT cGTGGGAGCT gCgCTGGCCG 360
ctGGCCTACT ctGGAAGTtC atGGGcAGCA aGTGCTCAA CTCTGGGATA gAGTGCgACT 420
cCTCAGGTAC ctGcATCAAC CCCTCTAAct gGTGTGATGG cGTGTcACAC tGCCCCGGCG 480
ggGAGGACGA gAAAtCGGTGT gttGcCCTt ACggACCAAa CTTCATCCTT cAGATGTACT 540
catCTCAGAG gAAAGTcCTGG cAccCTGTGt gCCAAGACGA ctGGAACGAG aACTACGGGc 600

```

gggcggcctg cagggacatg ggctataaga ataatttttta ctctagccaa ggaatagtgg 660
 atgacagcgg atcaccacgc tttatgaaac tgaacacaag tgccggcaat gtcgatatct 720
 ataaaaaaact gtaccacagt gatgcctgtt cttcaaaagc agtggtttct ttacgctgtt 780
 tagcctgcgg ggtaacttg aactcaagcc gccagagcag gatcggtggc ggtgagagcg 840
 cgctccccggg gcctggccc tggcaggta gcctgcacgt ccagaacgtc cacgtgtgcg 900
 gaggctccat catcaccccc gagtggatcg tgacagccgc ccactgcgtg gaaaaacctc 960
 ttaacaatcc atgcatttg acggcattt ggggatttt gagacaatct ttcatgttct 1020
 atggagccgg ataccaagta caaaaagtga ttttcatcc aaattatgac tccaagacca 1080
 agaacaatga cattgcgtg atgaagctgc agaagcctct gactttcaac gacctagtga 1140
 aaccagtgtg tctgcccac ccaggcatga tgctgcagcc agaacagctc tgctgattt 1200
 ccgggtgggg gcaccggag gagaaaggga agacctcaga agtgcgtgaa gctgccaagg 1260
 tgcttctcat tgagacacag agatgcacaac gcagatatgt ctatgacaac ctgatcacac 1320
 cagccatgat ctgtgccggc ttccctgcagg ggaacgtcga ttccctgcagg ggtgacagtg 1380
 gagggcctct ggtcacttcg aacaacaata tctgggtgc gatagggat acaagctggg 1440
 gttctggctg tgccaaagct tacagaccag gaggtgtacgg gaatgtgatg gtattcacgg 1500
 actggattta tcgacaaatg aaggcaaacg gctaattccac atggcttcg tccttgacgt 1560
 cgttttacaa gaaaacaatg gggctggtt tgctccccg tgcatttactcttagag 1620
 atgattcaga ggtcacttc tttttatcaa acagtgaact tgtctggct tggcactctc 1680
 tgccatactg tgcaaggctgc agtggctccc ctgcctcaggcc tgctctccct aacccttgt 1740
 ccccaagggg tgatggccgg ctggttgtgg gcactggcgg tcaattgtgg aaggaagagg 1800
 gttggaggct gccccattt agatcttcct gctgagtccct ttccaggggc caattttgga 1860
 tgagcatgga gctgtcactt ctcaagtcgatggactt agatgaaaaaa ggagagacat 1920
 ggaaagggg acagccagg ggcacctgca gggctgccc tctggggcca cttggtagtg 1980
 tccccagcct acttcacaag gggattttgc tgatgggttc ttagagcctt agcagccctg 2040
 gatggtgccca agaaataaaag ggaccagccc ttcatgggtg gtgacgtggt agtcaactgt 2100
 aaggggaaaca gaaacatttt tgttcttatg gggtggaaat atagacatgt cccttggtgc 2160
 gagggaaagca attgaaaagg aacttgcctt gggacttgcctt ggtgcagggtc tccacctgca 2220
 cattgggtgg ggctcctggg agggagactc agccttcctc ctcatctcc ctgaccctgc 2280
 tccttagacc ctggagagtg aatgcccctt ggtccctggc agggcgccaa gtttggcacc 2340
 atgtcggcct cttcaggcct gatagtcatggaaatggatg gttccatgggg gaaatcaagg 2400
 atgctcagtt taaggtacac tgttccatg ttatgttctt acacattgtatg ggtggtgacc 2460
 ctgagttcaa agccatctt 2479

<210> 10
 <211> 576
 <212> DNA
 <213> Homo sapiens

<400> 10
 ttccaaagaca tattagaagt tgggaaaata attcatgtga actagacaag tttgtttaaga 60
 gtgataagta aaatgcacgt ggagacaagt gcatccccag atctcaggaa cctcccccctg 120
 cctgtcacct ggggagttagtgg aggacagat agtgcattt ctttgcctt gaatttttag 180
 ttatatgtgc tttatgttg ctctgaggaa gcccctggaa agtctatccc aacatatacca 240
 catcttataat tccacaaatt aagctgttgtt atgtacccta agacgctgtt aattgtactgc 300
 cacttcgcaaa ctcaggggcg gctgcattt agtaatgggtt caaatgattt actttttatg 360
 atgcttccaa aggtgcctt gcttcttc ccaactgaca aatgccaagg ttgagaaaaaa 420
 tgatcataat tttagcataa acagagcagt cggcgcacacc gattttataaa ataaactgag 480
 caccttctt ttaaacaacaaac aaatgcgggt ttatgttctca gatgtgttc atccgtaat 540

ggtccagggga aggactttc accttacta tatggc 576

<210> 11
<211> 890
<212> DNA
<213> Homo sapiens

<400> 11
caagctctga ggcttctcct ttccatcctg cgtggacagc taagaccta gtttcaata 60
gcatctagag cagtggact cagctgggt gattcgccc cccatctccg gggaatgtc 120
tgaagacaat tttggttacc tcaatgaggg agtggaggag gatacagtgc tactaccaac 180
tagtggataa aggccaggg tgctgctaa cctcctacca tgtacaggga cgtctcccc 240
ttacaactac ccaatccgaa gtgtcaactg tgtcaggact aagaaaaccct ggttttgagt 300
agaaaaaggc ctgaaagag gggagccaac aaatctgtct gcttcctcac attagtcatt 360
ggcaaataag cattctgtct ctttggctgc tgccctcagca cagagagcca gaactctatc 420
gggcaccagg ataacatctc tcagtgaaca gagttgacaa ggcctatggg aaatgcctga 480
tgggattatc tttagttgt tgagcttcta agtttcttc ctttcattct accctgcaag 540
ccaagttctg taagagaaat gcctgaggta tagctcaggt tttcttactc tgaatttaga 600
tctccagacc cttccctggcc acaattcaaa ttaaggcaac aaacatatac cttccatgaa 660
gcacacacag acttttgaaa gcaaggacaa tgactgctt aattgaggcc ttgaggaatg 720
aagctttgaa ggaaaagaat actttgttc cagccccctt cccacactct tcatgtgtt 780
accactgcct tcctggaccc tggagccacg gtgactgtat tacatgttgt tatagaaaac 840
tgattttaga gttctgatcg ttcaagagaa tgattaaata tacatttcct 890

<210> 12
<211> 406
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (30)

<220>
<221> unsure
<222> (248)

<220>
<221> unsure
<222> (383)

<400> 12
gtgaatgtgg actataatgc cagctcagan accttgcgggt gtgaggctcc ccgatggttc 60
ccccagccca cagtggcttg ggcattccaa gttgaccagg gagccaactt ctcggaaatgc 120
tccaatacca gctttgagct gaactctgag aatgtgacca tgaaggttgt gtctgtgctc 180
tacaatgtta cgatcaacaa cacatactcc tgcgtatgattt aaaatgacat tgccaaagca 240
acaggggnta tcaaagtgc agaatcgag atcaaaaaggc ggagtcacct acagctgcta 300
aactcaaagg cttctctgtg tgcgttgcctt tcagctggc acttctgcct 360

ctcagccctt acctgatgct aanataatgt gccttgccca caaaaa 406

<210> 13
<211> 462
<212> DNA
<213> Homo sapiens

<400> 13
ggaaggcagc ggcaagctcca ctcagccagt acccagatac gctggaaacc ttccccagcc 60
atggcttccc tggggcagat cctttctgg agcataatta gcatcatcat tattctggct 120
ggagcaattt cactcatcat tggcttgggt atttcaggaa gacactccat cacagtcact 180
actgtcgccct cagctggaa cattggggag gatgaaatcc tgagctgcac ttttgaacct 240
gacatcaaac ttctgtatat cgtgatacaa tggctgaagg aagggtttt aggcttggtc 300
catgaggtaa aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagagccgg 360
acagcagtgt ttgctgatca agttagatgtt ggcaatgcct ctttgcggct gaaaaacgtg 420
caactcacag atgctggcac ctacaaatgt tatatcatca ct 462

<210> 14
<211> 272
<212> DNA
<213> Homo sapiens

<400> 14
gcagcttgct cagcggacaa ggatgctggg cgtagggac caaggcctgc cctgcactcg 60
ggcctcctcc agccagtgtt gaccaggac ttctgacactg ctggccagcc aggacctgtg 120
tggggaggcc ctcctgctgc ctgggggtga caatctcagc tccaggctac agggagaccg 180
ggaggatcac agagccagca tggatcctga cagtgtacaa cctctgaaca gcctcgtaa 240
ggtgattctg gataaataact acttcctctg cg 272

<210> 15
<211> 492
<212> PRT
<213> Homo sapiens

<400> 15
Met Ala Leu Asn Ser Gly Ser Pro Pro Ala Ile Gly Pro Tyr Tyr Glu
1 5 10 15

Asn His Gly Tyr Gln Pro Glu Asn Pro Tyr Pro Ala Gln Pro Thr Val
20 25 30

Val Pro Thr Val Tyr Glu Val His Pro Ala Gln Tyr Tyr Pro Ser Pro
35 40 45

Val Pro Gln Tyr Ala Pro Arg Val Leu Thr Gln Ala Ser Asn Pro Val
50 55 60

Val Cys Thr Gln Pro Lys Ser Pro Ser Gly Thr Val Cys Thr Ser Lys

65	70	75	80
Thr Lys Lys Ala Leu Cys Ile Thr Leu Thr Leu Gly Thr Phe Leu Val			
85	90	95	
Gly Ala Ala Leu Ala Ala Gly Leu Leu Trp Lys Phe Met Gly Ser Lys			
100	105	110	
Cys Ser Asn Ser Gly Ile Glu Cys Asp Ser Ser Gly Thr Cys Ile Asn			
115	120	125	
Pro Ser Asn Trp Cys Asp Gly Val Ser His Cys Pro Gly Gly Glu Asp			
130	135	140	
Glu Asn Arg Cys Val Arg Leu Tyr Gly Pro Asn Phe Ile Leu Gln Met			
145	150	155	160
Tyr Ser Ser Gln Arg Lys Ser Trp His Pro Val Cys Gln Asp Asp Trp			
165	170	175	
Asn Glu Asn Tyr Gly Arg Ala Ala Cys Arg Asp Met Gly Tyr Lys Asn			
180	185	190	
Asn Phe Tyr Ser Ser Gln Gly Ile Val Asp Asp Ser Gly Ser Thr Ser			
195	200	205	
Phe Met Lys Leu Asn Thr Ser Ala Gly Asn Val Asp Ile Tyr Lys Lys			
210	215	220	
Leu Tyr His Ser Asp Ala Cys Ser Ser Lys Ala Val Val Ser Leu Arg			
225	230	235	240
Cys Leu Ala Cys Gly Val Asn Leu Asn Ser Ser Arg Gln Ser Arg Ile			
245	250	255	
Val Gly Gly Glu Ser Ala Leu Pro Gly Ala Trp Pro Trp Gln Val Ser			
260	265	270	
Leu His Val Gln Asn Val His Val Cys Gly Ser Ile Ile Thr Pro			
275	280	285	
Glu Trp Ile Val Thr Ala Ala His Cys Val Glu Lys Pro Leu Asn Asn			
290	295	300	
Pro Trp His Trp Thr Ala Phe Ala Gly Ile Leu Arg Gln Ser Phe Met			
305	310	315	320
Phe Tyr Gly Ala Gly Tyr Gln Val Gln Lys Val Ile Ser His Pro Asn			

	325	330	335
Tyr Asp Ser Lys Thr Lys Asn Asn Asp Ile Ala Leu Met Lys Leu Gln			
340	345		350
Lys Pro Leu Thr Phe Asn Asp Leu Val Lys Pro Val Cys Leu Pro Asn			
355	360		365
Pro Gly Met Met Leu Gln Pro Glu Gln Leu Cys Trp Ile Ser Gly Trp			
370	375		380
Gly Ala Thr Glu Glu Lys Gly Lys Thr Ser Glu Val Leu Asn Ala Ala			
385	390		395
Lys Val Leu Leu Ile Glu Thr Gln Arg Cys Asn Ser Arg Tyr Val Tyr			
405	410		415
Asp Asn Leu Ile Thr Pro Ala Met Ile Cys Ala Gly Phe Leu Gln Gly			
420	425		430
Asn Val Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro Leu Val Thr Ser			
435	440		445
Asn Asn Asn Ile Trp Trp Leu Ile Gly Asp Thr Ser Trp Gly Ser Gly			
450	455		460
Cys Ala Lys Ala Tyr Arg Pro Gly Val Tyr Gly Asn Val Met Val Phe			
465	470		475
Thr Asp Trp Ile Tyr Arg Gln Met Lys Ala Asn Gly			
485	490		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19655

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C07K 16/8
US CL : 435/6, 7.1, 7.92; 530/387.1, 388.85

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1, 7.92; 530/387.1, 388.85 -

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
SEQ ID NO's 1-5 and 9-14

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Medline, CAPLUS, GenEmbl, N-Geneseg, USPATFULL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,939,258 A (CROCE et al) 17 August 1999, see col. 3, lines 1-22.	1-3
---P		-----
Y		4,5
X	US 5,733,748 A (YU et al) 31 March 1998, see abstract.	1-3
-----		-----
Y		4, 5

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A."	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
22 NOVEMBER 1999	07 FEB 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized office: LARRY HELMS Telephone No. (703) 308-0196 <i>Della Collins for</i>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19655

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PAOLONI-GIACOBNO et al. Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serine Protease with Transmembrane, LDLRA, and SRCK Domains and Maps to 21q22.3. Genomics. 1997, Vol. 44, pages 309-320, especially page 311.	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19655

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-9

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19655

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s)1-9, drawn to an in vitro method for diagnosing the presence of cancer by measuring the CSG levels in a patient with an antibody against CSG.

Group II, claim(s) 10-11, drawn to a method of in vivo imaging a selected cancer by administering an antibody with a paramagnetic ion or radioisotope label to the patient.

Group III, claim(s) 12-13, drawn to a method of in vivo treating a cancer in a patient comprising administering an antibody conjugated to a cytotoxic agent.

The inventions listed as Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The method of Group I recites the special technical feature of an in vitro diagnostic method to measure CSG levels that are not found in Groups II and III. The method of Group II recites the special technical features of an in vivo imaging method that is not found in Groups I and III. The method of Group III recites the special technical feature of in vivo treating a cancer using a cytotoxic agent that is not found in Groups I and II. Therefore, inventions of Groups I, II, and III do not relate to a single inventive concept under PCT Rule 13.1.